Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Duacept** is a small molecule oral contraceptive under development by **Arstat Pharmaceuticals**. It is specifically designed as a safer alternative to the leading European contraceptive pills for women of normal weight. The drug utilizes a **novel dosing regimen** intended to optimize efficacy while improving the safety profile compared to existing products. Duacept has received FDA endorsement for its clinical development program and is categorized as **Phase III-ready**, with Arstat Pharmaceuticals planning to initiate pivotal trials. It is part of a broader women's health pipeline that includes specialized contraceptives like Nuvocept (for overweight/obese women) and therapies for uterine conditions such as Premring and Enhanta.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Duacept.